miR-195在乳腺癌患者血浆中的表达及其临床意义

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (750 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the expression of miR-195 in plasma of patients with breast cancer in pre-operative and postoperative and two weeks and it correlation with clinicopathologic features of breast cancer. Methods: By normalized to miR-16, the expressions of miR-195 in 48 invasive ductal carcinoma of the breast cancer at preoperative and postoperative 2 weeks and 35 healthy controls were examined by stem-loop real-time RT-qPCR method. The relationship between miR-195 expression and clinicopathological characteristics were further analyzed. Results: Expression of miR-195 in plasma of patients with breast cancer was obviously higher than that in the healthy controls (P<0.05). At 2 weeks postopratively, a significant decrease of plasma miR-195 was observed, reaching levels of the healthy control subjects. ROC curve showed plasma levels of miR-195 could detect individuals with breast cancer with 94.4% sensitivity and 68.8% specificity. Correlative analysis of clinical features showed that there was no significant association between plasma miR-195 expression and the size of tumor, the state of ER, PR, lymph node metastasis and Her-2 receptor of breast cancer. Conclusion: Aberrant expression of miR-195 in plasma of breast cancer patients has potential use as novel noninvasive biomarkers for breast cancer.

Key words： microRNA miR-195 breast tumor

Received: 15 September 2013

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	XU Jiangang1
	LIN Feng2
	ZHANG Xianbo1
	HU Zhi3
	WANG Zhaojun1
	ZHAO Ting1
	SHEN Jie2.

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2014/V44/I2/105

[1] Weber JA, Baxter DH, Zhang S, et al. The microRNA spec-trum in 12 body fluids[J]. Clin Chem, 2010, 56(11): 1733-1741.

[2] Iguchi H, Kosaka N, Ochiya T. Secretory microRNAs as aversatile communication tool[J]. Commun Integr Biol, 2010,3(5): 478-481.

[3] Iguchi H, Kosaka N, Ochiya T. Versatile applications of microRNA in anti-cancer drug discovery: from therapeutics to biomarkers[J]. Curr Drug Discov Technol, 2010, 7(2):95-105.

[4] Kosaka N, Iguchi H, Yoshioka Y, et al. Competitive inter-actions of cancer cells and normal cells via secretory microRNAs[J]. J Biol Chem, 2012, 287(2): 1397-1405.

[5] Kosaka N, Iguchi H, Yoshioka Y, et al. Secretory mecha-nisms and intercellular transfer of microRNAs in living cells [J]. J Biol Chem, 2010, 285(23): 17442-17452.

[6] Soon PS, Tacon LJ, Gill AJ, et al. miR-195 and miR-483-5p Identified as Predictors of Poor Prognosis in Adrenocortical Cancer[J]. Clin Cancer Res, 2009, 15(24): 7684-7692.

[7] Liu L, Chen L, Xu Y, et al. microRNA-195 promotes apoptosis and suppresses tumorigenicity of human colorectal cancer cells[J]. Biochem Biophys Res Commun, 2010, 400 (2): 236-240.

[8] Yang X, Yu J, Yin J, et al. MiR-195 regulates cell apoptosis of human hepatocellular carcinoma cells by targeting LATS2 [J]. Pharmazie, 2012, 67(7): 645-651.

[9] Wu WY, Xue XY, Chen ZJ, et al. Potentially predictive microRNAs of gastric cancer with metastasis to lymph node [J]. World J Gastroenterol, 2011, 17(31): 3645-3651.

[10] Li D, Zhao Y, Liu C, et al. Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer[J]. Clin Cancer Res, 2011, 17(7): 1722-1730.

[11] Yang G, Wu D, Zhu J, et al. Upregulation of miR-195 in-creases the sensitivity of breast cancer cells to Adriamycin

treatment through inhibition of Raf-1[J]. Oncol Rep, 2013,30(2): 877-889.

[12] Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer[J]. Cancer Res,2005, 65(16): 7065-7070.

[13] Mattie MD, Benz CC, Bowers J, et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies[J]. Mol Cancer, 2006, 5(1): 24.

[14] Asaga S, Kuo C, Nguyen T, et al. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer[J]. Clin Chem, 2011, 57(1): 84-91.

[15] van Schooneveld E, Wouters MC, Van der Auwera I, et al.Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers[J]. Breast Cancer Res, 2012, 14(1): R34.

[16] Wu Q, Wang C, Lu Z, et al. Analysis of serum genome-wide microRNAs for breast cancer detection[J]. Clin Chim Acta,2012, 413(13-14): 1058-1065.

[17] 黄关立, 薛向阳, 曾瑞超, 等. 乳腺癌患者血浆中相关microRNA的表达及其临床意义[J]. 温州医学院学报, 2013,43(5): 286-290.

[18] Heneghan HM, Miller N, Lowery AJ, et al. CirculatingmicroRNAs as novel minimally invasive biomarkers forbreast cancer[J]. Ann Surg, 2010, 251(3): 499-505.

[19] Heneghan HM, Miller N, Kelly R, et al. Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease[J]. Oncologist, 2010, 15(7): 673-682.

[20] Vickers KC, Remaley AT. Lipid-based carriers of microRNAs and intercellular communication[J]. Curr Opin Lipidol, 2012,23(2): 91-97.

[21] Zhao H, Shen J, Medico L, et al. A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer[J]. PLoS One, 2010, 5(10): e13735.

[22] Chin LJ, Slack FJ. A truth serum for cancer-microRNAs have major potential as cancer biomarkers[J]. Cell Res, 2008,18(10): 983-984.

[23] Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases[J]. Cell Res, 2008, 18(10): 997-1006.